{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:04:29Z","timestamp":1792598669401,"version":"4.5.0"},"reference-count":61,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2012,5,22]],"date-time":"2012-05-22T00:00:00Z","timestamp":1337644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100009155","name":"Otsuka America Pharmaceutical, Inc., Rockville, MD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009155","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Hyponatremia, a common electrolyte abnormality in oncology practice, may be a negative prognostic factor in cancer patients based on a systematic analysis of published studies. The largest body of evidence comes from small-cell lung cancer (SCLC), for which hyponatremia was identified as an independent risk factor for poor outcome in six of 13 studies. Hyponatremia in the cancer patient is usually caused by the syndrome of inappropriate antidiuretic hormone (SIADH), which develops more frequently with SCLC than with other malignancies. SIADH may be driven by ectopic production of arginine vasopressin (AVP) by tumors or by effects of anticancer and palliative medications on AVP production or action. Other factors may cause hypovolemic hyponatremia, including diarrhea and vomiting caused by cancer therapy. Hyponatremia may be detected on routine laboratory testing before or during cancer treatment or may be suggested by the presence of mostly neurological symptoms. Treatment depends on several factors, including symptom severity, onset timing, and extracellular volume status. Appropriate diagnosis is important because treatment differs by etiology, and choosing the wrong approach can worsen the electrolyte abnormality. When hyponatremia is caused by SIADH, hypertonic saline is indicated for acute, symptomatic cases, whereas fluid restriction is recommended to achieve a slower rate of correction for chronic asymptomatic hyponatremia. Pharmacological therapy may be necessary when fluid restriction is insufficient. The orally active, selective AVP receptor 2 (V2)-receptor antagonist tolvaptan provides a mechanism-based option for correcting hyponatremia caused by SIADH or other conditions with inappropriate AVP elevations. By blocking AVP effects in the renal collecting duct, tolvaptan promotes aquaresis, leading to a controlled increase in serum sodium levels.<\/jats:p>","DOI":"10.1634\/theoncologist.2011-0400","type":"journal-article","created":{"date-parts":[[2012,5,24]],"date-time":"2012-05-24T00:48:26Z","timestamp":1337820506000},"page":"756-765","source":"Crossref","is-referenced-by-count":193,"title":["Diagnosis and Management of Hyponatremia in Cancer Patients"],"prefix":"10.1093","volume":"17","author":[{"given":"Jorge J.","family":"Castillo","sequence":"first","affiliation":[{"name":"a Division of Hematology and Oncology, The Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Vincent","sequence":"additional","affiliation":[{"name":"b Otsuka America Pharmaceutical, Inc., Rockville, Maryland, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Justice","sequence":"additional","affiliation":[{"name":"c BioScience Communications, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,5,22]]},"reference":[{"key":"2021122308231368800_B1","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1345\/aph.1D105","article-title":"Causes and management of hyponatremia","volume":"37","author":"Palmer","year":"2003","journal-title":"Ann Pharmacother"},{"key":"2021122308231368800_B2","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3121\/cmr.2007.762","article-title":"Tumor-related hyponatremia","volume":"5","author":"Onitilo","year":"2007","journal-title":"Clin Med Res"},{"key":"2021122308231368800_B3","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1056\/NEJM200005253422107","article-title":"Hyponatremia","volume":"342","author":"Adrogu\u00e9","year":"2000","journal-title":"N Engl J Med"},{"key":"2021122308231368800_B4","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.1995.13.5.1215","article-title":"Long-term survival in small-cell lung cancer: Posttreatment characteristics in patients surviving 5 to 18+ years\u2014an analysis of 1,714 consecutive patients","volume":"13","author":"Lassen","year":"1995","journal-title":"J Clin Oncol"},{"key":"2021122308231368800_B5","first-page":"4189","article-title":"Prognostic factors in small cell lung cancer: Multivariate model based on 778 patients treated with chemotherapy with or without irradiation","volume":"46","author":"\u00d8sterlind","year":"1986","journal-title":"Cancer Res"},{"key":"2021122308231368800_B6","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/0277-5379(90)90121-9","article-title":"Prognosis at presentation of small cell carcinoma of the lung","volume":"26","author":"Allan","year":"1990","journal-title":"Eur J Cancer"},{"key":"2021122308231368800_B7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.lungcan.2009.05.015","article-title":"The occurrence of hyponatremia in SCLC and the influence on prognosis: A retrospective study of 453 patients treated in a single institution in a 10-year period","volume":"68","author":"Hansen","year":"2010","journal-title":"Lung Cancer"},{"key":"2021122308231368800_B8","first-page":"463","article-title":"Tumor size, response rate, and prognosis in small cell carcinoma of the bronchus treated with combination chemotherapy","volume":"66","author":"Harper","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"2021122308231368800_B9","first-page":"67","article-title":"Atrial natriuretic factor and arginine vasopressin production in tumor cell lines from patients with lung cancer and their relationship to serum sodium","volume":"53","author":"Gross","year":"1993","journal-title":"Cancer Res"},{"key":"2021122308231368800_B10","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s00520-007-0309-9","article-title":"Diagnosis and management of hyponatremia in cancer patients","volume":"15","author":"Raftopoulos","year":"2007","journal-title":"Support Care Cancer"},{"key":"2021122308231368800_B11","first-page":"2878","article-title":"Prognostic significance of laboratory parameters measured at diagnosis in small cell carcinoma of the lung","volume":"45","author":"Souhami","year":"1985","journal-title":"Cancer Res"},{"key":"2021122308231368800_B12","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/ijc.2910390204","article-title":"Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients","volume":"39","author":"Cerny","year":"1987","journal-title":"Int J Cancer"},{"key":"2021122308231368800_B13","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/bjc.1990.133","article-title":"An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research","volume":"61","author":"Rawson","year":"1990","journal-title":"Br J Cancer"},{"key":"2021122308231368800_B14","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/jjco\/27.3.158","article-title":"Prognostic factors and prognostic staging system for small cell lung cancer","volume":"27","author":"Kawahara","year":"1997","journal-title":"Jpn J Clin Oncol"},{"key":"2021122308231368800_B15","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1023\/A:1008212826956","article-title":"Pretreatment prognostic factors for survival in small-cell lung cancer: A new prognostic index and validation of three known prognostic indices on 341 patients","volume":"8","author":"Maestu","year":"1997","journal-title":"Ann Oncol"},{"key":"2021122308231368800_B16","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1046\/j.1525-1500.1998.CDOA43.x","article-title":"Predictive factors of tumor response and prognostic factors of survival during lung cancer chemotherapy","volume":"22","author":"Ray","year":"1998","journal-title":"Cancer Detect Prev"},{"key":"2021122308231368800_B17","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4103\/0019-509X.25887","article-title":"Survival in small cell lung cancer in India: Prognostic utility of clinical features, laboratory parameters and response to treatment","volume":"43","author":"Mohan","year":"2006","journal-title":"Indian J Cancer"},{"key":"2021122308231368800_B18","first-page":"1379","article-title":"Prognostic factors in elderly patients with unresectable non-small cell lung cancer","volume":"21","author":"Kimura","year":"2001","journal-title":"Anticancer Res"},{"key":"2021122308231368800_B19","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/annonc\/mdn064","article-title":"OncoLR Health Network. Quality of life and comorbidity score as prognostic determinants in non-small-cell lung cancer patients","volume":"19","author":"Jacot","year":"2008","journal-title":"Ann Oncol"},{"key":"2021122308231368800_B20","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1158\/1078-0432.CCR-07-1721","article-title":"Prognostic factors in renal cell carcinoma: Association of preoperative sodium concentration with survival","volume":"14","author":"Vasudev","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2021122308231368800_B21","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/sj.bjc.6605563","article-title":"Hyponatremia as a prognostic and predictive factor in metastatic renal cell carcinoma","volume":"102","author":"Jeppesen","year":"2010","journal-title":"Br J Cancer"},{"key":"2021122308231368800_B22","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1159\/000127386","article-title":"Clinical outcome of gastric cancer patients with bone marrow metastases","volume":"73","author":"Kim","year":"2007","journal-title":"Oncology"},{"key":"2021122308231368800_B23","first-page":"523915","article-title":"Serum natrium determines outcome of treatment of advanced GIST with imatinib: A retrospective study of 80 patients from a single institution","volume":"2011","author":"Aggerholm-Pedersen","year":"2011","journal-title":"ISRN Oncol"},{"key":"2021122308231368800_B24","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/bjc.1993.425","article-title":"Combination therapy for intermediate and high grade non-Hodgkin's lymphoma","volume":"68","author":"Dhaliwal","year":"1993","journal-title":"Br J Cancer"},{"key":"2021122308231368800_B25","doi-asserted-by":"crossref","first-page":"R137","DOI":"10.1186\/cc8016","article-title":"Admission factors associated with hospital mortality in patients with haematological malignancy admitted to UK adult, general critical care units: A secondary analysis of the ICNARC Case Mix Programme Database","volume":"13","author":"Hampshire","year":"2009","journal-title":"Crit Care"},{"key":"2021122308231368800_B26","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.amjmed.2009.01.027","article-title":"Mortality after hospitalization with mild, moderate, and severe hyponatremia","volume":"122","author":"Waikar","year":"2009","journal-title":"Am J Med"},{"key":"2021122308231368800_B27","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1053\/j.ajkd.2011.08.029","article-title":"Hyponatremia in hospitalized cancer patients and its impact on clinical outcomes","volume":"59","author":"Doshi","year":"2012","journal-title":"Am J Kidney Dis"},{"issue":"suppl 1","key":"2021122308231368800_B28","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.amjmed.2007.09.001","article-title":"Hyponatremia treatment guidelines 2007: Expert panel recommendations","volume":"120","author":"Verbalis","year":"2007","journal-title":"Am J Med"},{"key":"2021122308231368800_B29","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.semnephrol.2008.03.009","article-title":"Vasopressin and aquaporin 2 in clinical disorders of water homeostasis","volume":"28","author":"Schrier","year":"2008","journal-title":"Semin Nephrol"},{"key":"2021122308231368800_B30","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1164\/ajrccm.156.5.96-10075","article-title":"A prospective study of patients with lung cancer and hyponatremia of malignancy","volume":"156","author":"Johnson","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"2021122308231368800_B31","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1158\/1078-0432.CCR-05-1536","article-title":"A metabolic study of patients with lung cancer and hyponatremia of malignancy","volume":"12","author":"Chute","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2021122308231368800_B32","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1200\/JCO.1986.4.8.1191","article-title":"The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in small-cell lung cancer","volume":"4","author":"List","year":"1986","journal-title":"J Clin Oncol"},{"key":"2021122308231368800_B33","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2796.1995.tb00907.x","article-title":"Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant disease","volume":"238","author":"S\u00f8rensen","year":"1995","journal-title":"J Intern Med"},{"key":"2021122308231368800_B34","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1177\/000348949210101111","article-title":"Syndrome of inappropriate secretion of arginine vasopressin in patients with cancer of the head and neck","volume":"101","author":"Talmi","year":"1992","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"2021122308231368800_B35","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1177\/000348949710601014","article-title":"Syndrome of inappropriate antidiuretic hormone secretion associated with head and neck cancers: Review of the literature","volume":"106","author":"Ferlito","year":"1997","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"2021122308231368800_B36","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1001\/archinte.1973.03650110061013","article-title":"Vincristine neurotoxicity and abnormal secretion of antidiuretic hormone","volume":"132","author":"Robertson","year":"1973","journal-title":"Arch Intern Med"},{"key":"2021122308231368800_B37","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1182\/blood.V45.3.315.315","article-title":"Syndrome of recurrent increased secretion of antidiuretic hormone following multiple doses of vincristine","volume":"45","author":"Stuart","year":"1975","journal-title":"Blood"},{"key":"2021122308231368800_B38","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1053\/j.ajkd.2008.03.004","article-title":"A review of drug-induced hyponatremia","volume":"52","author":"Liamis","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"2021122308231368800_B39","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/1097-0142(197909)44:3<896::AID-CNCR2820440316>3.0.CO;2-9","article-title":"A fatal case of inappropriate ADH secretion induced by cyclophosphamide therapy","volume":"44","author":"Harlow","year":"1979","journal-title":"Cancer"},{"key":"2021122308231368800_B40","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/archinte.1985.00360030196034","article-title":"Water intoxication following moderate-dose intravenous cyclophosphamide","volume":"145","author":"Bressler","year":"1985","journal-title":"Arch Intern Med"},{"key":"2021122308231368800_B41","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1097\/SMJ.0b013e3181e63682","article-title":"Cisplatin-induced renal salt wasting syndrome","volume":"103","author":"Hamdi","year":"2010","journal-title":"South Med J"},{"key":"2021122308231368800_B42","doi-asserted-by":"crossref","first-page":"62","DOI":"10.7812\/TPP\/08-066","article-title":"Hyponatremia\u2014what is cerebral salt wasting?","volume":"14","author":"Momi","year":"2010","journal-title":"Permanente J"},{"issue":"suppl 1","key":"2021122308231368800_B43","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.amjmed.2006.05.003","article-title":"Brain volume regulation in response to hypo-osmolality and its correction","volume":"119","author":"Sterns","year":"2006","journal-title":"Am J Med"},{"key":"2021122308231368800_B44","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1159\/000086019","article-title":"Consequences of inadequate management of hyponatremia","volume":"25","author":"Adrogu\u00e9","year":"2005","journal-title":"Am J Nephrol"},{"issue":"suppl 3","key":"2021122308231368800_B45","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.3949\/ccjm.73.Suppl_3.S4","article-title":"Hyponatremia: Why it matters, how it presents, how we can manage it","volume":"73","author":"Douglas","year":"2006","journal-title":"Clev Clin J Med"},{"key":"2021122308231368800_B46","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3810\/hp.2010.02.283","article-title":"Hyponatremia: Evaluation and management","volume":"38","author":"Zenenberg","year":"2010","journal-title":"Hosp Pract (Minneap)"},{"key":"2021122308231368800_B47","first-page":"672","volume-title":"Clinical Physiology of Acid-Base and Electrolyte Disorders","author":"Rose","year":"1994","edition":"Fourth Edition"},{"key":"2021122308231368800_B48","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0272-6386(12)80647-0","article-title":"The electrolytes in hyponatremia","volume":"18","author":"Graber","year":"1991","journal-title":"Am J Kidney Dis"},{"key":"2021122308231368800_B49","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1002\/jhm.703","article-title":"Four nephrology myths debunked","volume":"6","author":"Rachoin","year":"2011","journal-title":"J Hosp Med"},{"issue":"suppl 1","key":"2021122308231368800_B50","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1530\/EJE-09-1057","article-title":"The syndrome of inappropriate antidiuretic hormone: Current and future management options","volume":"162","author":"Sherlock","year":"2010","journal-title":"Eur J Endocrinol"},{"issue":"suppl 3","key":"2021122308231368800_B51","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.3949\/ccjm.73.Suppl_3.S24","article-title":"AVP receptor antagonists as aquaretics: Review and assessment of clinical data","volume":"73","author":"Verbalis","year":"2006","journal-title":"Cleve Clin J Med"},{"key":"2021122308231368800_B52","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1093\/jjco\/hyq170","article-title":"Clinical implication of the antidiuretic hormone (ADH) receptor antagonist mozavaptan hydrochloride in patients with ectopic ADH syndrome","volume":"41","author":"Yamaguchi","year":"2011","journal-title":"Jpn J Clin Oncol"},{"key":"2021122308231368800_B53","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2147\/DDDT.S4505","article-title":"Conivaptan and its role in the treatment of hyponatremia","volume":"3","author":"Ghali","year":"2009","journal-title":"Drug Des Devel Ther"},{"key":"2021122308231368800_B54","volume-title":"Samsca\u2122 (tolvaptan) tablets for oral use [prescrib-ing information]","year":"2009"},{"key":"2021122308231368800_B55","first-page":"860","article-title":"OPC-41061, a highly potent human vasopressin V2-receptor antagonist: Pharmacological profile and aquaretic effect by single and multiple oral dosing in rats","volume":"287","author":"Yamamura","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"2021122308231368800_B56","doi-asserted-by":"crossref","first-page":"F273","DOI":"10.1152\/ajprenal.00195.2005","article-title":"Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure","volume":"290","author":"Costello-Boerrigter","year":"2006","journal-title":"Am J Physiol Renal Physiol"},{"key":"2021122308231368800_B57","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa065181","article-title":"SALT Investigators. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia","volume":"355","author":"Schrier","year":"2006","journal-title":"N Engl J Med"},{"key":"2021122308231368800_B58","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1530\/EJE-10-1078","article-title":"Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion","volume":"164","author":"Verbalis","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"2021122308231368800_B59","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.jhep.2011.08.020","article-title":"Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis","volume":"56","author":"C\u00e1rdenas","year":"2012","journal-title":"J Hepatol"},{"key":"2021122308231368800_B60","volume-title":"Summary of Product Characteristics","author":"Samsca\u2122 (tolvaptan) Tablets (2009) Annex I"},{"key":"2021122308231368800_B61","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1681\/ASN.2009080857","article-title":"SALTWATER Investigators. Oral tolvaptan is safe and effective in chronic hyponatremia","volume":"21","author":"Berl","year":"2010","journal-title":"J Am Soc Nephrol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2011-0400","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2011-0400","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/17\/6\/756\/41859799\/oncolo_17_6_756.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/17\/6\/756\/41859799\/oncolo_17_6_756.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T21:52:24Z","timestamp":1640296344000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/17\/6\/756\/6400954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,22]]},"references-count":61,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2012,5,22]]},"published-print":{"date-parts":[[2012,6,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2011-0400","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,6,1]]},"published":{"date-parts":[[2012,5,22]]}}}